These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. Tai WT, Chu PY, Shiau CW, Chen YL, Li YS, Hung MH, Chen LJ, Chen PL, Su JC, Lin PY, Yu HC, Chen KF. Clin Cancer Res; 2014 Nov 15; 20(22):5768-76. PubMed ID: 25248379 [Abstract] [Full Text] [Related]
3. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF. Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751 [Abstract] [Full Text] [Related]
4. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma. Saraswati S, Alhaider A, Abdelgadir AM, Tanwer P, Korashy HM. Cell Commun Signal; 2019 Oct 16; 17(1):127. PubMed ID: 31619257 [Abstract] [Full Text] [Related]
5. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. Liu CY, Huang TT, Chu PY, Huang CT, Lee CH, Wang WL, Lau KY, Tsai WC, Chao TI, Su JC, Chen MH, Shiau CW, Tseng LM, Chen KF. Exp Mol Med; 2017 Aug 11; 49(8):e366. PubMed ID: 28798401 [Abstract] [Full Text] [Related]
6. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF. Hepatology; 2014 Jan 11; 59(1):190-201. PubMed ID: 23908138 [Abstract] [Full Text] [Related]
7. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW. Cancer Lett; 2012 Aug 01; 321(1):27-35. PubMed ID: 22465052 [Abstract] [Full Text] [Related]
8. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF. Mol Cancer Ther; 2012 Feb 01; 11(2):452-63. PubMed ID: 22180308 [Abstract] [Full Text] [Related]
9. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL. Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479 [Abstract] [Full Text] [Related]
10. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF. J Hepatol; 2011 Nov 15; 55(5):1041-8. PubMed ID: 21354226 [Abstract] [Full Text] [Related]
11. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Sethi G. J Cell Physiol; 2012 May 15; 227(5):2184-95. PubMed ID: 21792937 [Abstract] [Full Text] [Related]
12. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF. Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051 [Abstract] [Full Text] [Related]
13. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Hui KM, Sethi G. Br J Pharmacol; 2013 Oct 28; 170(4):807-21. PubMed ID: 23848338 [Abstract] [Full Text] [Related]
14. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW. Carcinogenesis; 2014 Dec 28; 35(12):2807-14. PubMed ID: 25322871 [Abstract] [Full Text] [Related]
15. ZnAs@SiO2 nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, Mei C, Yan Y, Jin H, Gao J, Su Z, Pang P, Li D, Shan H. Theranostics; 2019 Dec 28; 9(15):4391-4408. PubMed ID: 31285768 [Abstract] [Full Text] [Related]
16. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model. Tai WT, Shiau CW, Li YS, Chen YL, Chu PY, Huang JW, Hsu CY, Hsu YC, Chen PJ, Chen KF. Mol Cancer Ther; 2014 Jan 28; 13(1):27-36. PubMed ID: 24275147 [Abstract] [Full Text] [Related]
17. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q, Cao P. Cancer Lett; 2013 Jan 28; 328(2):243-51. PubMed ID: 23032719 [Abstract] [Full Text] [Related]
18. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. Huang CY, Tai WT, Wu SY, Shih CT, Chen MH, Tsai MH, Kuo CW, Shiau CW, Hung MH, Chen KF. Int J Radiat Oncol Biol Phys; 2016 Jun 01; 95(2):761-71. PubMed ID: 26960749 [Abstract] [Full Text] [Related]
19. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. Pei T, Meng Q, Han J, Sun H, Li L, Song R, Sun B, Pan S, Liang D, Liu L. Oncotarget; 2016 Jul 12; 7(28):43475-43491. PubMed ID: 27259268 [Abstract] [Full Text] [Related]
20. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K. Clin Cancer Res; 2011 Mar 15; 17(6):1373-81. PubMed ID: 21131553 [Abstract] [Full Text] [Related] Page: [Next] [New Search]